Clinical trial · Interventional
The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE
The Effects of Single Dose Oxycodone Versus Sufentanil on Pain and Inflammatory Response After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: a Randomized Controlled Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this randomized, double-blind trial was to compare the effects of preemptive Oxycodone and sufentanil at the same dose on pain and inflammatory response after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma. To study the effect of single dose intravenous injection of Oxycodone and sufentanil before TACE on inflammatory reaction after TACE; And (ii) evaluate the effects of different opioid drugs on pain and nausea/vomiting after TACE.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Inflammation | — | UNRESOLVED | — |
| Pain | — | UNRESOLVED | — |
| Transcatheter Arterial Chemoembolization | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oxycodone | Drug | — | UNRESOLVED |
| Sufentanil | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Oxycodone
- description
- The patients were given 0.1mg/kg oxycodone 15 minutes before transcatheter arterial chemoembolization (TACE).
- interventionNames
- Drug: Oxycodone
- type
- ACTIVE_COMPARATOR
- label
- Sufentanil
- description
- The patients were given 0.1μg/kg sufentanil 15 minutes before transcatheter arterial chemoembolization (TACE).
- interventionNames
- Drug: Sufentanil
Primary outcomes (5)
- measure
- Intraoperative pain intensity during TACE.
- timeFrame
- Intraoperative (From the beginning of TACE to the end of TACE.)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years; * Presence of histologically confirmed or clinically diagnosed hepatocellular carcinoma (fulfilling the criteria for lesions with typical imaging); * Presence of Child-Pugh class A or B disease; * Absence of benefit from a treatment of established efficacy such as resection and local ablation; * ECOG:0-2. Exclusion Criteria: * Extrahepatic metastasis and/or microvascular invasion; * Severe liver and kidney dysfunction; * Uncontrolled or significant cardiovascular disease; Autoimmune hepatitis; Long term use of opioids, steroid hormones, and non steroidal anti-inflammatory drugs; Abnormal elevation of C-reactive protein (CRP); Increased white blood cells (\>11000/mm3); Study Drugs allergy; Patients who were treated within 4 weeks after COVID-19 infection was diagnosed.
References
Publications (1)
- DERIVEDWu WT, Xu BJ, Li B, Hang Y, Zu QQ, Zhou WZ, Liu S, Shi HB, Chen Y. Pre-emptive Oxycodone versus Sufentanil for Acute and Delayed Pain after Transcatheter Arterial Chemoembolization: A Randomized Controlled Trial with Inflammatory Biomarker Analysis. J Vasc Interv Radiol. 2026 May;37(5):108570. doi: 10.1016/j.jvir.2026.108570. Epub 2026 Jan 30. PMID 41621790